Opioid rotation: Logical choices for pain that is poorly responsive to morphine

Progress in Palliative Care

Volumn 17, Issue 3, 2009, Pages 111-116

  Prommer, Eric E ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

Morphine; Opioid responsiveness; Opioid rotation; Pain

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHOLECYSTOKININ; CODEINE; CORTICOSTEROID; DRUG METABOLITE; FENTANYL CITRATE; GLUCOCORTICOID; KETAMINE; METHADONE; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE RECEPTOR; OXYCODONE; RADIOISOTOPE; SAMARIUM 153; STRONTIUM 89;

ALLODYNIA; ANALGESIA; ANESTHESIOLOGICAL TECHNIQUES; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER PAIN; CANCER PATIENT; CANCER RADIOTHERAPY; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERANCE; DRUG TREATMENT FAILURE; EDEMA; FIRST PASS EFFECT; FRACTURE; HUMAN; HYPERALGESIA; INTERNALIZATION; MYOCLONUS; NEUROPATHIC PAIN; ORTHOPEDIC SURGERY; PAIN; PHARMACODYNAMICS; RECEPTOR INTRINSIC ACTIVITY; REGIONAL ANESTHESIA; REVIEW;

EID: 70350153624     PISSN: 09699260     EISSN: 1743291X     Source Type: Journal    
DOI: 10.1179/096992609X392312     Document Type: Review

References (36)

1. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43: 273-286.
2. World Health Organization. Cancer Pain Relief: Report of a WHO Expert Committee. Geneva: WHO, 1996.
3. Hanks GW, Conno F, Cherny N et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001; 84: 587-593.
4. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M. Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 1999; 23: 737-746.
5. Finn AK, Whistler JL. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001; 32: 829-839.
6. Koch T, Brandenburg LO, Schulz S, Liang Y, Klein J, Hollt V. ADPribosylation factor-dependent phospholipase D2 activation is required for agonist-induced mu-opioid receptor endocytosis. J Biol Chem 2003; 278: 9979-9985.
7. Lotsch JR. Opioid metabolites. J Pain Symptom Manage 2005; 29 (Suppl 1): 10-24.
8. Andersen G, Christrup L, Sjøgren P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. J Pain Symptom Manage 2003; 25: 74-91.
9. Sjøgren P, Dragsted L, Christensen CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993; 37: 780-782.
10. Tiseo PJ, Thaler HT, Lapin J, Inturrisi CE, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47-54.
11. Connor M, Osborne PB, Christie MJ. Mu-opioid receptor desen - sitization: is morphine different? Br J Pharmacol 2004; 143: 685-696.
12. Keith DE, Anton B, Murray SR et al. mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. Mol Pharmacol 1998; 53: 377-384.
13. Mao J. Opioid tolerance and neuroplasticity. Novartis Found Symp 2004; 261: 181-186.
14. McCleane G. Cholecystokinin antagonists a new way to improve the analgesia from old analgesics? Curr Pharm Des 2004; 10: 303-314.
15. Benarroch EE. Descending monoaminergic pain modulation: bidirectional control and clinical relevance. Neurology 2008; 71: 217-221.
16. Mao J, Price DD, Mayer DJ. Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions. Pain 1995; 62: 259-274.
17. Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage 2005; 30: 485-491. (Pubitemid 41718968)
18. Luger NM, Mach DB, Sevcik MA, Mantyh PW. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage 2005; 29 (Suppl. 1): 32-46.
19. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 2006; 10: 67-70.
20. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 2: Basic mechanisms that could shift dose response for analgesia. J Pain Symptom Manage 2001; 21: 255-264.
21. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: Clinical considerations. J Pain Symptom Manage 2001; 21: 144-150.
22. Coller JK, Christrup LL, Somogyi AA. Role of active metabolites in the use of opioids. Eur J Clin Pharmacol 2009; 65: 121-139.
23. Davis MP, Varga J, Dickerson D, Walsh D, LeGrand SB, Lagman R. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Support Care Cancer 2003; 11: 84-92.
24. Bruera E, Kim HN. Cancer pain. JAMA 2003; 290: 2476-2479.
25. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 1999; 86: 1856-1866.
26. Ripamonti C, Zecca E, Brunelli C et al. Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 1995; 6: 841-843.
27. Bruera E, Sweeney C. Methadone use in cancer patients with pain: a review. J Palliat Med 2002; 5: 127-138.
28. Mercadante S. Ketamine in cancer pain: an update. Palliat Med 1996; 10: 225-230.
29. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000; 20: 246-252.
30. Davis MP, Shaiova LA, Angst MS. When opioids cause pain. J Clin Oncol 2007; 25: 4497-4498.
31. Mercadante S, Sapio M, Caligara M, Serretta R, Dardanoni G, Barresi L. Opioid-sparing effect of diclofenac in cancer pain. J Pain Symptom Manage 1997; 14: 15-20.
32. Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 2007; 19: 308-314.
33. Woo SB, Kalmar JR. Osteonecrosis of the jaws and bisphos - phonates. Alpha Omegan 2007; 100: 194-202.
34. von Moos R, Strasser F, Gillessen S, Zaugg K. Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer 2008; 16: 1105-1115.
35. Wong GY, Schroeder DR, Carns PE et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004; 291: 1092-1099.
36. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001; 21: 338-354. (Pubitemid 32331888)